KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Asset Writedowns and Impairment (2016 - 2019)

Arbutus Biopharma's Asset Writedowns and Impairment history spans 4 years, with the latest figure at $43.8 million for Q3 2019.

  • For Q3 2019, Asset Writedowns and Impairment rose 195.97% year-over-year to $43.8 million; the TTM value through Dec 2020 reached $58.6 million, changed 0.0%, while the annual FY2019 figure was $43.8 million, 195.97% up from the prior year.
  • Asset Writedowns and Impairment for Q3 2019 was $43.8 million at Arbutus Biopharma, up from $14.8 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $156.3 million in Q2 2016 and bottomed at $1.0 million in Q4 2015.
  • The 4-year median for Asset Writedowns and Impairment is $40.9 million (2015), against an average of $58.5 million.
  • The largest annual shift saw Asset Writedowns and Impairment surged 9425.37% in 2016 before it surged 195.97% in 2019.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $1.0 million in 2015, then soared by 9425.37% to $96.9 million in 2016, then crashed by 84.71% to $14.8 million in 2018, then soared by 195.97% to $43.8 million in 2019.
  • Per Business Quant, the three most recent readings for ABUS's Asset Writedowns and Impairment are $43.8 million (Q3 2019), $14.8 million (Q3 2018), and $96.9 million (Q4 2016).